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ABSTRACT: A structure-based design of a new generation of
tumor-associated glycopeptides with improved affinity against
two anti-MUC1 antibodies is described. These unique antigens
feature a fluorinated proline residue, such as a (4S)-4-fluoro-L-
proline or 4,4-difluoro-L-proline, at the most immunogenic
domain. Binding assays using biolayer interferometry reveal
3-fold to 10-fold affinity improvement with respect to the
natural (glyco)peptides. According to X-ray crystallography
and MD simulations, the fluorinated residues stabilize the
antigen−antibody complex by enhancing key CH/π inter-
actions. Interestingly, a notable improvement in detection of cancer-associated anti-MUC1 antibodies from serum of patients
with prostate cancer is achieved with the non-natural antigens, which proves that these derivatives can be considered better
diagnostic tools than the natural antigen for prostate cancer.
■ INTRODUCTION
MUC1 is a glycoprotein overexpressed in around 80% of human
cancers.1−3 It consists of an extracellular domain that comprises
a variable number (20 to 125) of tandem repeat regions formed
by 20 amino acids (His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-
Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala). This domain in-
cludes five potential O-glycosylation sites, with three threonine
(Thr) and two serine (Ser) residues. While in healthy cells,
the MUC1 backbone displays complex oligosaccharides, in
tumors it is decorated with basic, truncated carbohydrates.
Consequently, different tumor-associated carbohydrate antigens
(TACAs), such as the Tn determinant (α-O-GalNAc-Ser/Thr),
become exposed and are involved in triggering immune
responses.4−7 Because of this unique feature, extensive efforts
have been made toward the development of cancer vaccines
based on MUC1 fragments.8−12
In addition, over the years, several studies have demonstrated
that circulating anti-MUC1 antibodies in serum may be used
as a favorable prognosis for patients with early breast and
pancreatic cancer because these antibodies can limit tumor
outgrowth and dissemination.13−18 Consequently, efforts have
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been devoted toward the rational design of MUC1-based
antigens to be used as diagnostic tools for detection of anti-
MUC1 antibodies in human serum. Unfortunately, so far, a
commercial assay for early cancer diagnosis based on the
detection of anti-MUC1 antibodies in human serum remains
unavailable. However, significant advances toward this aim were
reported by Wang and co-workers,19 where they described an
assay based on a recombinant MUC1 protein that contained
six MUC1 tandem repeats and was effective in detecting anti-
MUC1 antibodies in serum from patients. More recently, a
chimera containing both MUC1 and human epidermal growth
factor receptor-2 (HER2), whose overexpression is associated
with malignancy in breast cancer, has been developed for detec-
tion of antibodies against MUC1 or HER2 in human serum.20
It should be noted that, in these examples, antibody detection
relies on unmodified naturally occurring antigens.
Alternatively, fine-tuning of antibody/antigen interactions by
exploiting non-natural, synthetically designed antigen modifications
holds great potential in the development of diagnostic detection
systems with improved selectivity and sensitivity. This strategy
demands a precise understanding of the molecular basis of
the antigen−antibody recognition process. In this regard, recent
progress unveiled subtle molecular details of the antibody/
antigen interaction,21,22 paving the way to the structure-based
design of synthetic antigens with improved potential value in
diagnosis and detection. In this context, it has been shown
that most anti-MUC1 antibodies display a significant affinity to
peptide fragments containing the APDTRP sequence,23 which
consequently represents an attractive target for lead optimization.
Our group has recently described the X-ray structure of a
short peptide bearing the sequence APDT(α-O-GalNAc)RP in
complex with the SM3,22 which is a therapeutic antibody used
in the treatment of cancer.21 According to these data, the
nonterminal Pro residue plays a central role in the stabilization
of the antibody/antigen complex, stacking against aromatic
units of Trp91L, Trp96L, and Tyr32L (Figure 1). This obser-
vation explains why a proline residue at this position of
the antigen is indeed essential for the binding of various anti-
MUC1 antibodies.24 Interestingly, recent studies have shown
that CH/π bonds can be significantly enhanced by simply
increasing the polarization of the interacting CH moieties.25−28
In the present work, this effect could be achieved by attaching
highly electronegative fluorine atoms to specific positions of the
proline scaffold. Therefore, we hypothesized that the replace-
ment of the nonterminal proline residue of the antigen by a
non-natural proline derivative, such as (4S)-4-fluoro-L-proline
or 4,4-difluoro-L-proline, should enhance antigen−antibody
affinity (Figure 1).
Here, we designed and synthesized various MUC1 antigens
that featured a hydrogen-by-fluorine substitution at that proline
residue that displayed enhanced affinity to two anti-MUC1
antibodies. By combining molecular dynamic (MD) simulations
and X-ray crystallography, we provide an explanation of the
superior affinity of our derivatives toward two antibodies, which
relies on stronger CH/π interactions. Finally, we demonstrate
that these novel derivatives are more efficient than natural
antigens in detecting low concentrations of circulating anti-
MUC1 antibodies in human serum of patients with prostate
cancer (adenocarcinoma and benign prostatic hyperplasia).
■ RESULTS AND DISCUSSION
To provide theoretical support for the hypothesis depicted in
Figure 1, we calculated the electrostatic potential surface of the
Figure 1. Hydrogen-by-fluorine Pro replacement strategy to improve antibody−antigen affinity. Crystal structure of glycopeptide APDT(α-O-GalNAc)RP
in complex with antibody SM3 (pdb ID: 5a2k) together with the strategy proposed in this work to design effective antigens based on MUC1.
Figure 2. Effect of fluorine atoms on the electrostatic potential and on
CH/π stability. (A) Electrostatic potential surfaces (in au) calculated at
the M06-2X/6-31+G(d,p) level in a vacuum, showing the re faces
of the Pro derivatives. Blue/red indicates positive/negative potentials.
(B) Binding energy calculated at the M06-2X/6-31+G(d,p) level in a
vacuum for the three Pro derivatives with an indole residue, together with
the optimized distance Pro−indole ring for the complexes.
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proline and its mono- and difluorinated derivatives shown in
Figure 2A. In a second step, their interaction energies with an
indole ring were evaluated at the M06-2X/6-31+G(d,p) level of
theory.29 The obtained relative energies were in agreement with
our rational design and showed that the fluorinated residues
displayed an enhanced positive partial charge on the CH/π
donor methylene fragments (highlighted with a red circle in
Figure 2A). As a result, the interacting proline face displays a
significantly larger electrostatic potential even for the mono-
substituted derivative (4S)-4-fluoro-L-proline. This polarization
effect is reflected in the theoretical interaction energies, with
complex stabilizations larger than 1 kcal/mol (Figure 2B).
With these data in hand, we decided to synthesize a series of
peptides and glycopeptides comprising the tandem repeat
sequence of MUC1 (Figure 3) both fluorinated and nonfluo-
rinated at position 8. The synthesis of all these derivatives
was conducted using microwave-assisted solid phase peptide
synthesis (MW-SPPS), employing a Rink amide MBHA resin
and Fmoc-protected amino acids and using our reported
protocol30 (Supporting Information).
We then evaluated the impact of the hydrogen-by-fluorine
substitutions on the antigen association to antibody scFv-
SM322 using biolayer interferometry (BLI). Although both
natural peptide P and glycopeptide P* act as antigens, it has
been observed that the latter displays better affinity than the
naked peptide (Figure 4A).22,23 This trend is also noted for
the non-natural derivatives. To our delight, surrogates fP*
and 2fP*, which contain a (4S)-4-fluoro-L-proline or a
4,4-difluoro-L-proline at position 8, respectively, showed the
best affinity, with ca. 3-fold enhancement with respect to the
natural P* and 1 order of magnitude regarding natural pep-
tide P. In parallel, we performed microarray assays31,32
to determine the affinity of these MUC1 variants with com-
mercially available antibodies SM3 and VU-3C623 (Figure 4B).
The results obtained from the microarray experiments were in
line with the BLI data, showing a clear increase in binding affinity
for the non-natural variants. This result may indicate that both
SM3 and VU-3C6 antibodies recognize the antigen with an
equivalent binding mode.
Figure 3. MUC1-like peptides and glycopeptides synthesized and
studied in this work.
Figure 4. Binding of the glycopeptides to anti-MUC1 antibodies. (A) BLI curves and fit obtained for glycopeptide fP* and antibody scFv-SM3,
together with the KD constants derived from BLI experiments for all studied MUC1-related compounds. (B) Interaction of the anti-MUC1 antibody
VU-3C6 with the glycopeptides using a microarray platform. Compounds were printed onto an aminooxy-functionalized microarray in
quadruplicate. Relative fluorescence units (RFU) due to the binding of the Cy3-labeled secondary antibody were measured and represented as mean
values in a bar chart (see Supporting Information for experimental details).
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To fully validate our molecular design, we carried out
detailed structural studies on our fluorinated antigens in com-
plex with the antibody SM3. To this purpose, we synthesized a
simplified variant of glycopeptide fP*, comprising the sequences
GVTSAfPDT*RPAP and denoted as fP*′ throughout the
Article. High-quality crystals of fP*′ in complex with scFv-SM3
were obtained, which enabled the acquisition of a structure at
high resolution (<2.0 Å, Figure 5A and Supporting Information).
Crystallographic analysis revealed that the conformation of the
glycopeptide was almost identical to that found for peptide
SAPDTRPAP and for glycopeptide APDT(α-O-GalNAc)RP in
complex with the same antibody.21,22 This outcome suggests
that the incorporation of a fluorine atom at the proline residue
does not significantly modify the structure of the peptide in the
bound state (Figure 5B). Consequently, the antigen−antibody
hydrogen-bonding network is identical to that found in the
previously reported complexes.21,22 The obtained results also
indicate that GalNAc glycosylation does not have an influence
on the accommodation of the key proline residue (compare
5a2k and 5a2j in Figure 5C). In fact, the glycosidic linkage
adopts the expected exoanomeric/syn conformation, with ϕ and ψ
values of ∼68 and 91°, respectively. This conformation is
similar to that found for a Tn-glycopeptide in complex with
SM3 (pdb ID: 5a2k)22 and allows the formation of an inter-
molecular hydrogen bond between the hydroxymethyl group
of GalNAc and the side chain of Tyr32L of the antibody.
Moreover, the N-acetyl group of the sugar stacks with the
aromatic ring of Trp33H, which provides the driving force
for the observed selectivity of SM3 for GalNAc-containing
antigens. Despite all these similarities, the obtained crystallo-
graphic coordinates revealed a subtle but crucial modification
with previously reported structural data. Markedly, the observed
distance between the center of the (4S)-4-fluoro-L-proline ring
and Trp91L was significantly smaller than that observed for the
Pro−Trp pairs in other complexes (Figure 5C). This result
provides further support to our premise, strongly suggesting that
Figure 5. Crystal structure of fP*′ bound to scFv-SM3. (A) Key binding interactions of glycopeptide fP*′ with scFv-SM3 mAb, as observed in the
X-ray crystal structure (pdb ID: 5OWP). Peptide backbone carbon atoms are shown in yellow. GalNAc carbon atoms are shown in cyan. Carbon atoms
of key residues of SM3 are in slate. The antibody is shown as gray ribbons. Pink dashed lines indicate hydrogen bonds between peptide backbones and
SM3 antibody. It is important to note that only residues SAPDTRP of the peptide could be resolved, presumably due to the higher flexibility of the rest
of the amino acids. (B) Superposition of the peptide backbone of glycopeptides fP*′ and APDT(α-O-GalNAc)RP, together with SAPDTRPAP
peptide21 in complex with SM3. The root-mean-square deviation (rmsd) of the backbone is shown. (C) Experimental distances Pro−Trp91L obtained
from X-ray structures of various MUC1-like derivatives in complex with antibody SM3.
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the improvement in the proline/tryptophan stacking accounts
for the increased stability of the complexes formed by the non-
natural fluorinated antigens.
The influence exerted by proline fluorination on the antigen/
SM3 complexes was also analyzed by MD simulations.
Thus, we collected 200 ns trajectories on 2fP*′ and fP*′
bound to scFv-SM3 (Figure 6A). MD simulations on the
reduced versions of natural glycopeptide (P*′) complexed to
the antibody were also conducted for comparative purposes.
According to these theoretical data, the three complexes
were stable through the simulations. Most importantly, a
shorter distance between Pro and Trp91L was found for
derivate fP*′ (with a distance Pro−Trp91L = 4.0 ± 0.4 Å), in
agreement with the X-ray structure described in Figure 5, and
for compound 2fP*′ (distance Pro−Trp91L = 4.1 ± 0.6 Å).
In contrast, the distance found for the natural glycopeptide P*′
was 4.7 ± 0.4 Å. In summary, both experimental and theoretical
data confirm the validity of our design and show that improving
proline/tryptophan stacking-type interaction through simple
hydrogen-by-fluorine substitutions represents a simple way to
stabilize the antigen/antibody complex. These results hint that
the tailored fluorinated MUC1 glycopeptides can be employed
as potential antigens for the efficient detection of anti-MUC1
antibodies.
With this purpose, we established an indirect ELISA
(Supporting Information) assay using both P* and non-natural
MUC1 2fP* as coating antigens to detect anti-MUC1 anti-
bodies from serum samples of patients with benign and
malignant prostate tumors. As can be observed in Figure 7, the
signal-to-noise ratio was statistically higher when 2fP* was
used for both adenocarcinoma and benign hyperplasia. Our study
also shows a higher concentration of anti-MUC1 antibodies in
malignant tumors, which agrees with other assays conducted with
breast tumor patients19 and importantly validates our protocol.
The results disclosed here demonstrate the potential appli-
cation of the designed 2fP* MUC1 variant as a biomarker for
improved detection of circulating anti-MUC1 antibodies in the
serum of patients.
■ CONCLUSIONS
A multidisciplinary approach to unravel key features of MUC1
recognition has been established. In particular, a new set of
non-natural MUC1 derivatives comprising a (4S)-4-fluoro-L-
proline or 4,4-difluoro-L-proline residue at the most immuno-
genic domain have been designed and synthesized. These
compounds present a clear enhancement in the binding affinity
against two anti-MUC1 antibodies with respect to the natural
antigens. Both experimental X-ray studies and theoretical MD
simulations confirm that, in agreement with our expectations,
the hydrogen-by-fluorine substitution enhances the key CH/π
interaction, which is crucial for improving the binding of the
antigen to the antibody. Moreover, the obtained glycopeptides
Figure 6. MD simulations of glycopeptide 2fP*′ in complex with scFv-SM3. (A) Representative frame of the 200 ns MD simulations performed on
2fP*′ in complex with antibody scFv-SM3. Only peptide fragment Ser4-Ala11 is shown for clarity. Peptide backbone carbon atoms are shown in
yellow. GalNAc carbon atoms are shown in cyan. Carbon atoms of key residues of SM3 are in slate. The antibody is shown as gray ribbons.
(B) Distance distribution of Pro−Trp91L obtained from 200 ns MD simulations for glycopeptides P*′ (upper panel), fP*′ (middle panel), and
2fP*′ (lower panel) bound to the antibody SM3.
Figure 7. Detection of circulating anti-MUC1 antibodies in serum of
patients presenting benign and malignant prostate cancer. Binding
affinity of human circulating antibodies against MUC1 (P*) and
synthetic variant 2fP*, in the context of prostate adenocarcinoma and
benign prostatic hyperplasia. Bars show average ± standard error of the
mean of absorbance values normalized to healthy controls. All groups
were compared to P* using Wilcoxon matched-pairs signed rank test;
*p < 0.05; **p < 0.02 (see Supporting Information for details).
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display a significant potential as diagnostic tools to detect anti-
MUC1 antibodies in prostate cancer patients.
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